This European multicenter study compares the efficacy and tolerance of the combination of pyrimethamine-clindamycin (Pyr-Cm) with the standard therapy pyrimethamine-sulfadiazine (PyrSdz) for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS. Two hundred ninetynine human immunodeficiency virus-infected patients with TE were randomly assigned to receive 50 mg of pyrimethamine daily combined with either 2,400 mg of clindamycin or 4 g of sulfadiazine for 6 weeks followed by maintenance therapy with 25 mg of pyrimethamine daily with either 1,200 mg of clindamycin or 2 g of sulfadiazine. An intent-to-treat analysis showed that Pyr-Cm was less effective than Pyr-Sdz; the overall risk of progression of TE was 1.84 times higher for patients receiving Pyr-Cm therapy. There was no statistically significant difference in efficacy during acute therapy, although the rate of crossover motivated by a lack of response was higher among Pyr-Cm recipients. The difference in efficacy was evidenced during the maintenance phase of treatment; the relapse rate was twice as high among patients in the Pyr-Cm group (P = .02). The rate of side effects due to both regimens was similar, although the toxic effects of Pyr-Cm led to fewer discontinuations of therapy than did those of Pyr-Sdz (11% vs. 30%, respectively; P = .001). Pyr-Sdz appears to be the most effective treatment of TE. Pyr-Cm is a valuable alternative but is less effective for long-term prevention of relapses.
Toxoplasmic encephalitis (TE) is the most common opportunistic infection of the CNS in patients with AIDS. The frequency of TE depends on the prevalence of Toxoplasma gondii infection in the general population; it varies from 5%-10% in the United States to 10%-40% in Europe [1, 2] .
The current recommended therapy for TE is the combination pyrimethamine-sulfadiazine (Pyr-Sdz). The major problem with this potent antitoxoplasmic combination is poor tolerance [3] [4] [5] . The extensive use of sulfonamides as primary prophylaxis for Pneumocystis carinii pneumonia led to a decrease in the incidence of toxoplasmosis; however, a relatively higher number of cases occurs in patients intolerant to these drugs, thus highlighting the need for an alternative treatment to sulfonamides. Clindamycin has been shown to be effective in vitro and in murine models [6, 7] . Several small nonrandomized studies showing that clindamycin was effective therapy for patients intolerant to sulfonamides [8 -1 0] prompted us to prospectively evaluate the efficacy and safety of pyrimethamineclindamycin (Pyr-Cm) as both acute and maintenance therapy. Recent published data have confirmed the efficacy of Pyr-Cm in the acute phase of treatment [11, 12] . We present here the results of a long-term prospective comparison of Pyr-Sdz and Pyr-em as acute and maintenance therapy for TE.
Patients and Methods
This European, multicenter, randomized, prospective study was designed as an open-label trial. Patients were randomly assigned to receive either Pyr-Cm or Pyr-Sdz as acute therapy and then as lifelong maintenance therapy.
Patients infected with HIV type 1 who presented with their first episode of TE (defined as fever and/or neurological symptoms or signs and the presence of at least one contrast-enhancing brain lesion on a CT) were eligible for entry into the study. Patients were excluded from the study for the following reasons: a previous episode of cerebral toxoplasmosis, a previous severe intolerance to the study drugs, or a poor hematologic profile (defined as a neutrophil count of <0.75 X 10 9 /L, a hemoglobin level of <8 g/dL, and/or a platelet count of <50 X 10 9 /L). Pyrimethamine was given orally (50 mg daily) combined with either oral c1indamycin (2.4 g daily in four divided doses) or sulfadiazine (4 g daily in four divided doses) during 6 weeks. A minimum weekly dose of 50 mg of folinic acid was administered in both treatment arms. All medications justi-fied by patient conditions were permitted except for other antitoxoplasmic drugs. Because of a risk of cumulative hematotoxic effects, zidovudine treatment was not recommended during acute therapy. Lifelong maintenance therapy consisted of pyrimethamine (25 mg daily) combined with either clindamycin (300 mg four times daily) or sulfadiazine (500 mg four times daily), with a minimum of 50 mg of folinic acid weekly.
Patient Management and Measurements
During acute therapy patients underwent complete clinical and neurological examinations at entry and at weeks 1, 2, 4, and 6. Neurological signs and symptoms-hemiplegia/hemiparesis, cranial nerve deficit, sensory deficit, cerebellar abnormality, aphasia, visual disorders, alteration of consciousness, seizures, and headache-were graded as absent, moderate, or severe. Crossover to the other arm of treatment was allowed ifthe patient's evaluation showed no improvement or deterioration of the clinical status after a minimal duration of 7 days of therapy. CT was performed at study enrollment and at the end of acute therapy. The same radiographic imaging procedure was used throughout the study for each patient, and reading of the images was made by the same radiologist who was unaware of the patient's clinical condition and treatment. Laboratory studies, including complete blood cell count, serum chemistry analysis, and liver enzyme tests, were performed at the same time points as the clinical evaluation.
Adverse reactions were scored by means of the WHO scale for toxic effects. Mild-to-moderate adverse events (grades 1 and 2) were treated symptomatically. Patients with severe toxic effects (grades 3 and 4) or adverse reactions that persisted despite symptomatic therapy were crossed over to the other treatment arm. Hematologic toxic effects were managed as follows: if the neutrophil count fell to <0.75 X 109/L or the platelet count fell to < 50 X 10 9 /L, the dose of folinic acid was doubled; if the neutrophil count remained <0.5 X 109/L despite doubling the dose of folinic acid, pyrimethamine therapy was discontinued until the neutrophil count increased to 0.75 X 10 9 /L. In the case of persistent neutropenia, treatment was discontinued.
During maintenance therapy patients underwent clinical and neurological evaluation every 2 months. If any acute neurological manifestation occurred, neuroradiological imaging was performed, and acute antitoxoplasmic therapy was reinstituted in the case of a focal abnormality. Adverse events were managed the same way as during the acute phase of treatment.
Clinical efficacy was based on the results of both acute and maintenance therapy. Successful therapy was defined as a complete response (i.e., disappearance of all signs or symptoms of TE at week 6) or a partial response (i.e., decrease or disappearance of active signs or symptoms of TE with persistence of stable neurological sequelae at week 6) and the absence of any recurrent brain mass lesion during maintenance therapy. Disease progression was defined as a lack of response (i.e., persistence or increase of signs and symptoms at week 6) or death due to any cause during acute therapy or the recurrence of a brain mass lesion during maintenance therapy. The diagnosis of relapse of TE during maintenance therapy was assessed either by brain biopsy or by a favorable response to reinduction therapy. Other brain mass lesions were classified as either other CNS diagnoses (i.e., lesions histologically not related to toxoplasma infection) or no definitive diagnosis (i.e., lesions that did not respond to antitoxoplasmic therapy and were not histologically documented).
Radiological response to acute therapy was classified as a complete response (i.e., disappearance of all initial lesions in the absence of any new lesion), a partial response (i.e., a > 50% decrease in the number of lesions and/or the size of initial lesions in the absence of any new lesion), or no response (i.e., a <50% decrease in the number and/or size of the brain lesions or an increase in the number of lesions and/or the size of any initial lesion).
Analysis
The sample size was calculated to ensure an 80% power for detecting a difference of 15% in the response to acute therapy between the two treatment arms. The projected rate of efficacy for the Pyr-Sdz group was 90%. Thus, an efficacy of <75% for the Pyr-Cm group was considered as clinically significant (two-tailed test). Such a 15% difference could be detected with 80% power at a significance level of a = 0.05 with 226 evaluable patients. To compensate for deaths due to unrelated causes, drug intolerance, and loss to follow-up, we attempted to enroll a total of 300 patients. Patients were randomized with blocks at each site by means of opening sealed envelopes sequentially.
The analyses included all patients, with the exception of those who were not eligible for study entry. Unless noted otherwise, all statistical analyses were performed on an intent-totreat basis. Clinical response at the end of induction therapy (including the proportion of complete responders and the overall proportion of responders) and the kinetics of response were estimated as a function of time by the Kaplan-Meier product limit method and were compared by the logrank test. The proportion ofpatients with adverse reactions during induction therapy was compared by the X 2 test or Fisher's exact test, according to the sample size. The time to progression was computed from the date of randomization to the date of the first documented relapse. Patients for whom acute therapy failed were considered to have failure at week 6. Patients who did not receive maintenance treatment for other reasons were censored at the end ofthe acute therapy. Relapse rates indicated for specific time points have been estimated by the same method (I-progression free rate).
The number of patients who crossed over during the acute phase of therapy was compared by the X 2 test. With regard to the reasons for crossover, the patients were classified in three categories (no crossover, crossover due to progression, and (12) NOTE. Unless stated otherwise, data are no. (%) of patients with indicated characteristic. Cm = c1indamycin; Pyr = pyrimethamine; Sdz = sulfadiazine; TE = toxoplasmic encephalitis.
* Nine patients had more than one risk factor. crossover due to toxic effects), and the X 2 test with 2 df was used to compare therapeutic arms. For the overall duration of therapy, the probability of remaining in the allocated treatment group while still receiving therapy was estimated by the Kaplan-Meier product limit method and compared by the logrank test.
Results

Study Population
A total of 340 patients were enrolled iil the study over a 1-year period; 31 clinical centers in eight European countries participated in the study. Forty-one patients (22 in the Pyr-Cm group and 19 in the Pyr-Sdz group) were ineligible for study; the reasons were equally distributed between both treatment arms. Of the 299 remaining patients, 152 were randomized to Pyr-Cm, and 147 were randomized to Pyr-Sdz. Fourteen patients were treated with drug regimens that differed from the one recommended by the protocol (concomitant treatment with a sulfonamide, 6 patients in the Pyr-Cm group; inadequate dose of sulfadiazine, 8 patients in the Pyr-Sdz group). These patients are included in the intent-to-treat analysis. One patient randomized to clindamycin was erroneously treated with sulfadiazine. This patient is included in the analysis of his treatment arm. The demographic and baseline clinical characteristics of the 299 patients are summarized in table 1. The two treatment groups were well balanced with respect to all baseline clinical and radiological characteristics measured except for sensory deficit.
Efficacy of Treatment
The overall risk of progression of TE in recipients of PyrCm was 1.84 times higher than that in recipients of Pyr-Sdz; the median time to disease progression was 42 weeks in the Pyr-Cm group and 116 weeks in the Pyr-Sdz group (P = .009; logrank test) (figure 1).
Acute Therapy Acute therapy was successful with a complete or partial response in 103 (68%; 95% CI, 60%-70%) of the 152 patients in the Pyr-Cm group and in 112 (76%; 95% CI, 69%-83%) of the 147 patients in the Pyr-Sdz group. Although there was a trend for a better efficacy of Pyr-Sdz, this difference was not statistically significant (P = .105; X 2 test) (table 2). The time course of the neurological response did not statistically differ between the two groups. The probability of resolution of hemiplegia/hemiparesis was 32% in the Pyr-Cm group vs. 41 % in the Pyr-Sdz group (P = .43; logrank test) and the probability of resolution of alteration of consciousness was 67% in the Pyr-Cm group vs. 59% in the Pyr-Sdz group (P = .58; logrank test).
There was a lack of response or progression of disease in 64 patients (21%)-38 (25%) in the Pyr-Cm group and 26 (18%) in the Pyr-Sdz group. No difference in terms of etiology was noted between the treatment arms. Of these 64 patients, nine had histologically proven TE (6 Pyr-Cm recipients and 3 Pyr-Sdz recipients). Thirteen patients (5 Pyr-Cm recipients vs. 8 Pyr-Sdz recipients) had another diagnosis proven by biopsy: brain lymphoma (9), progressive multifocalleukoencephalopathy (2), brain infarct (1), and HIV encephalopathy (1). In the absence of a brain specimen, no definitive diagnosis could be made for the remaining 42 patients (27 Pyr-Cm recipients vs. 15 Pyr-Sdz recipients); neurological deterioration in these patients was attributed to the following: toxoplasmosis (15), lymphoma (10), leukoencephalopathy (4), AIDS dementia complex (3), cytomegalovirus infection (2), cerebral metastasis (1), and undetermined (7). Thirty-five of these 42 patients underwent T. gondii serology, which was positive for 31 (89%)-21 PyrCm recipients and 10 Pyr-Sdz recipients. Treatment of20 other patients (II Pyr-Cm recipients and 9 Pyr-Sdz recipients) failed because of extraneurological complications.
Two hundred seventy-two patients were radiologically evaluable: the number of patients with a complete response, a partial response, and no response was 41 (29%), 69 (50%), and 29 (21 %) of 139 Pyr-Cm recipients vs. 42 (32%), 75 (56%), and 16 (12%) of 133 Pyr-Sdz recipients.
A total of 82 patients crossed over to the other arm of treatment; there was no statistically significant difference in the o o crossover rate between the groups: 37 patients (24%) in the Pyr-Cm group and 45 patients (31 %) in the Pyr-Sdz group. However, the reasons for crossing over differed significantly between the two groups (P < .0005). Most crossovers from sulfadiazine to clindamycin (44 of 45) were due to drug side effects, whereas those from clindamycin to sulfadiazine (20 of 37) were due to lack of response (table 2) . Of the 20 recipients of Pyr-Cm who crossed over, the conditions of 6 subsequently improved with sulfadiazine, treatment failed for 3 who had biopsy-proven TE, 2 had another biopsy-proven condition, and 9 had no definitive diagnosis.
Maintenance Therapy NOTE. Cm = clindamycin; Pyr = pyrimethamine; Sdz = sulfadiazine; TE = toxoplasmic encephalitis. One hundred seventy-five patients (59% of the initial patients) who responded to acute therapy entered the maintenance phase of treatment (93 in the Pyr-Cm group vs. 82 in the PyrSdz group [initial treatment arm]). Although patients were not rerandomized and received maintenance therapy that was the same as the combination used at the end of acute therapy, both groups remained comparable in terms of demographic and clinical characteristics. An intent-to-treat analysis showed that 32 and 20 patients initially randomized to clindamycin and sulfadiazine, respectively, had a reappearance of a brain mass lesion during a median follow-up period of 89 weeks and> 130 weeks (P = .02; logrank test), respectively. The overall risk of relapse of TE was two times higher for patients initially randomized to c1indamycin (20 cases in the Pyr-Cm group and 9 in the Pyr-Sdz group) (table 3). The rate of relapse was also evaluated as a function of the treatment at the start of maintenance therapy; there were 35 relapses in the 92 patients who started maintenance treatment with c1indamycin and 17 in those 83 who started maintenance treatment with sulfadiazine. The risk of relapse was 2.16 times higher for patients treated in the maintenance phase with c1indamycin than with sulfadiazine. Of the Pyr-Cm and Pyr-Sdz recipients who had relapse of TE, 20 and 12 adequately took both drugs, 5 and 4 used reduced doses, and 7 and 4 discontinued their treatment, respectively. Adverse Effects of Therapy
The incidence of adverse reactions during acute and maintenance therapy was similar in the two treatment groups (table  4) . During acute therapy toxic effects leading to crossover were significantly more frequent in the Pyr-Sdz group (44 [30%] of 147 patients) than in the Pyr-Cm group (17 [11%] of 152 patients) (P ::= .0001). Diarrhea was more frequent in the PyrCm group (19%) than in the Pyr-Sdz group (5%) (P ::= .0007). Skin rash and fever were more frequent and severe in the PyrSdz group (39%) than in the Pyr-Cm group (29%). Four patients died of severe adverse events (Clostridium difJicile pseudomembranous colitis in two Pyr-Cm recipients and acute epidermolysis in two Pyr-Sdz recipients). During maintenance therapy the frequency of adverse events due to the study drugs was similar in both treatment groups. Diarrhea occurred more frequently with clindamycin, and rashes (including acute epidermolysis and Stevens-Johnson syndrome in one patient each) were more frequent with sulfadiazine.
Survival
Survival did not significantly differ between the two groups (median survival: 38 weeks, Pyr-Cm group; 49 weeks, PyrSdz group; P ::= .27; logrank test) (figure 2). A total of 160 deaths were recorded. Fifty-one patients (29 Pyr-Cm recipients vs. 22 Pyr-Sdz recipients) died during acute therapy. Death was related to neurological disorders in 18 Pyr-Cm recipients and 12 Pyr-Sdz recipients. Postmortem examination showed TE in nine cases and lymphoma in four cases. No definitive diagnosis could be made for the remaining 17 patients. During maintenance therapy, treatment groups were similar with respect to mortality rate (51 deaths in the Pyr-Cm group vs. 58 deaths in the Pyr-Sdz group) and cause of death.
Discussion
This randomized, prospective study showed that Pyr-Sdz is more effective than Pyr-Cm in the overall treatment of TE, including acute and maintenance phases of treatment. Side effects were equally frequent in both treatment groups, although they were more severe with Pyr-Sdz. No difference in survival was observed between the two treatment groups.
The trial was analyzed on an intent-to-treat basis to minimize bias inherent to this type of clinical trial, such as the absence of diagnostic certainty, the urgency of treatment, the absence of alternative therapy besides the two treatment arms, and the frequency of associated brain disease with difficult diagnostic ::: patients randomized to pyrimethaminesulfadiazine (Pyr-Sdz); i+ = patients randomized to pyrimethamineclindamycin (Pyr-em). Months from start oftreatment assessment (including rarity of postmortem diagnosis). The clinical efficacy was evaluated in regard to both acute and maintenance therapy to take into account the natural history of TE as a whole. When considering the acute phase of therapy, no statistically significant difference in efficacy could be detected, although a trend in favor of Pyr-Sdz was noted. Moreover, a higher number of patients had to discontinue clindamycin therapy because of a poor clinical response. The lack of statistical difference is in accordance with the other published randomized, comparative trial of Pyr-Cm and Pyr-Sdz [11] . The trend that was noted in our study could be explained by the larger population included and the different clindamycin regimen (2.4 g daily orally vs. 4.8 g daily intravenously).
Published studies on acute therapy for TE have shown the efficacy of regimens using a wide range of doses (pyrimethamine, 25-100 mg; sulfadiazine, 2-8 g; clindamycin, 1.2-4.8 g) [9] [10] [11] [12] [13] . This study evaluated relatively low daily doses. The rate of clinical response during acute therapy (68%, Pyr-Cm; 76%, Pyr-Sdz) is comparable with those reported in other studies using higher doses [11, 12] .
One could argue that the unblinded design of the study could have biased the rate of crossover because of poor response. However, this rate remained constant during the duration of the trial, which suggests that crossovers were not due to the fear of investigators of using a new therapy (data not shown). Moreover, treatment of80% ofthe patients who did not respond to clindamycin was switched after at least 10 days, a period usually sufficient for appreciating clinical improvement [1] . This apparent higher efficacy of Pyr-Sdz in vivo is consistent with what has been found in murine models; these models have shown that Pyr-Sdz is superior to other combinations, including Pyr-Cm [14] .
The presence of antibodies to Toxoplasma was not required as an eligibility criteria given the high prevalence of positivity found in Europe and the fact that TE was not unequivocally associated with positive toxoplasma serology at the time the study was designed. However, results of toxoplasma serology were collected in case of an inadequate clinical response and were positive in 90% of the cases.
Pyr-Sdz was more effective than Pyr-Cm in preventing relapses of cerebral toxoplasmosis. The median time to relapse of toxoplasmic disease was significantly longer in the Pyr-Sdz group than in the Pyr-Cm group. The relapse rate of proven toxoplasmosis was also significantly decreased in the Pyr-Sdz group when data were analyzed on the basis of the drug received at entry into the maintenance phase of treatment.
Open-label, retrospective, noncomparative, small-sample studies have also suggested that the efficacy of Pyr-Cm as maintenance therapy for TE is lower [5, 15, 16] . Higher doses of clindamycin could improve efficacy but would probably lead to greater toxic effects and could generate compliance problems. In addition to its higher antitoxoplasmic activity, the reported efficacy of Pyr-Sdz as primary prophylaxis for P. carinii pneumonia is another argument for preferring long-term maintenance therapy with this combination [17, 18] .
The major drawback of Pyr-Sdz is poor tolerance [3, 14, 19] . Our results are consistent with data from previous studies reporting rates of toxic effects of 40%-62% [4, 5, 11] . The frequency of side effects was also high with Pyr-Cm, but these effects led to less crossovers. Cutaneous hypersensitivity was frequent; however, rashes were less severe, and discontinuation of therapy was required for only 3% of patients. As expected, diarrhea commonly complicated the use of clindamycin and was the most frequent adverse reaction leading to crossover.
A significant proportion of patients had adverse effects potentially related to antitoxoplasmic treatment during maintenance therapy (20% in the Pyr-Cm group and 28% in the PyrSdz group). It is of interest that eight of the 10 patients with rash due to sulfadiazine had been previously exposed for sev-cm 1996;22 (February) eral weeks to high doses of sulfadiazine during acute therapy without having any hypersensitivity reaction. This delayed appearance of hypersensitivity might be due to a decline of immune status over time that induced a higher risk of drug intolerance. Bone marrow suppression was not a major problem during maintenance therapy, and concomitant use of zidovudine did not result in a higher incidence of hematotoxic effects, thus suggesting that zidovudine therapy can be maintained for most patients receiving the doses of antitoxoplasmic agents used in this trial (data not shown).
In conclusion, the combination Pyr-Sdz should be considered as the standard therapy for TE mostly in view of its higher efficacy in preventing relapses during maintenance therapy. Pyr-Cm is a reliable alternative when sulfadiazine cannot be used. The high rate of intolerance to both combinations requires the development of new antitoxoplasmic agents suitable for both treatment and prophylaxis. At this time, atovaquone and new macrolides have been considered as alternative agents mostly Jor salvage acute therapy. However, their place in the treatment ofcerebral toxoplasmosis remains poorly defined and will probably be difficult to establish through large comparative trials because of various reasons, including the declining incidence of the disease due to wider use of primary prophylaxis.
